Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin‐induced lung injury

Abstract

Roflumilast prevented the development of bleomycin-induced lung injury, and alleviated the lung fibrotic and vascular remodeling response to bleomycin in a therapeutic protocol, the latter being resistant to glucocorticoids.